These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 38733703)
1. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome. Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C Clin Neurophysiol; 2024 Jul; 163():132-142. PubMed ID: 38733703 [TBL] [Abstract][Full Text] [Related]
2. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347 [TBL] [Abstract][Full Text] [Related]
3. Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy. Larue M; Bouvier A; Maillard A; Cuffel A; Allain V; Ursu R; Carpentier AF; Azoulay E; Thieblemont C; Di Blasi R; Caillat-Zucman S J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39317455 [TBL] [Abstract][Full Text] [Related]
4. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616 [TBL] [Abstract][Full Text] [Related]
6. EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity. Gust J; Annesley CE; Gardner RA; Bozarth X J Clin Neurophysiol; 2021 Mar; 38(2):135-142. PubMed ID: 31851018 [TBL] [Abstract][Full Text] [Related]
7. Impact of diagnostic investigations in the management of CAR T-cell-associated neurotoxicity. Mauget M; Lemercier S; Quelven Q; Maamar A; Lhomme F; De Guibert S; Houot R; Manson G Blood Adv; 2024 May; 8(10):2491-2498. PubMed ID: 38501964 [TBL] [Abstract][Full Text] [Related]
9. EEG-based grading of immune effector cell-associated neurotoxicity syndrome. Jones DK; Eckhardt CA; Sun H; Tesh RA; Malik P; Quadri S; Firme MS; van Sleuwen M; Jain A; Fan Z; Jing J; Ge W; Nascimento FA; Sheikh IS; Jacobson C; Frigault M; Kimchi EY; Cash SS; Lee JW; Dietrich J; Westover MB Sci Rep; 2022 Nov; 12(1):20011. PubMed ID: 36414694 [TBL] [Abstract][Full Text] [Related]
10. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Strati P; Nastoupil LJ; Westin J; Fayad LE; Ahmed S; Fowler NH; Hagemeister FB; Lee HJ; Iyer SP; Nair R; Parmar S; Rodriguez MA; Samaniego F; Steiner RE; Wang M; Pinnix CC; Adkins S; Claussen CM; Martinez CS; Hawkins MC; Johnson NA; Singh P; Mistry HE; Horowitz S; George S; Feng L; Kebriaei P; Shpall EJ; Neelapu SS; Tummala S; Chi TL Blood Adv; 2020 Aug; 4(16):3943-3951. PubMed ID: 32822484 [TBL] [Abstract][Full Text] [Related]
11. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Miller A; Daum R; Wang T; Wu M; Tat C; Pfeiffer T; Navai S; Heczey A; Hegde M; Ahmed N; Whittle SB; Hill L; Martinez C; Krance R; Ramos CA; Rouce RH; Lulla P; Heslop HE; Omer B; Shekar M Cytotherapy; 2024 Sep; 26(9):1026-1032. PubMed ID: 38819365 [TBL] [Abstract][Full Text] [Related]
12. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma. Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285 [TBL] [Abstract][Full Text] [Related]
13. Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis. Tang JP; Lafeuille P; Socolov A; Diamond SS; Aptekar J; Moore TB; Nie EH; Hanudel MR; Nowicki TS Cancer Res Commun; 2024 Oct; 4(10):2589-2597. PubMed ID: 39269033 [TBL] [Abstract][Full Text] [Related]
14. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score. Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. Gu T; Hu K; Si X; Hu Y; Huang H WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757 [TBL] [Abstract][Full Text] [Related]